课题基金 / 基金详情

Potent Lipoglycopeptide Antibiotics Against C. Difficile

Potent Lipoglycopeptide Antibiotics Against C. Difficile
针对艰难梭菌的强效脂糖肽抗生素
批准号:
nhmrc : 1063214
负责人:
Prof Matthew Cooper
金额:
$50.04万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2014
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2014-01-01 至 2016-12-31

项目摘要

项目成果

Prof Matthew Cooper的其他基金

相似基金

相关文献

中文摘要
翻译
在一些人体内,艰难梭菌自然存在于肠道中。其他人在医院或疗养院就诊时,意外地摄入了这种细菌的孢子。有时,用于治疗感染的广谱抗生素也会杀死健康的肠道细菌。然后肠道中充满艰难梭菌,导致腹泻和疼痛,有时甚至死亡。我们将研究一种新的有效抗生素万卡匹林的使用,以杀死艰难梭菌并防止感染复发。
英文摘要
In some people C. difficile bacteria naturally reside in the gut. Other people accidentally ingest spores of the bacteria while they are patients in a hospital or nursing home. Sometimes, broad-spectrum antibiotics used to treat an infection also kill healthy gut bacteria. The gut then becomes overrun with C. difficile, causing diarrhoea and pain, and sometimes death. We will investigate the use of a new potent antibiotic, vancapticin, to kill C. difficle and prevent relapse of infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the roles and mechanisms of activation of NLRP3 inflammasomes and developing therapeutic interventions for severe steroid-resistant asthma
  • 批准号:
    nhmrc : 1120252
  • 项目类别:
    Project Grants
  • 资助金额:
    $65.65万
  • 财政年份:
    2017
  • 负责人:
    Prof Matthew Cooper
  • 依托单位:
Novel NLRP3 Inhibitors for Steroid Resistant Asthma
  • 批准号:
    nhmrc : 1118973
  • 项目类别:
    Development Grants
  • 资助金额:
    $63.26万
  • 财政年份:
    2017
  • 负责人:
    Prof Matthew Cooper
  • 依托单位:
Altering the microbiome to treat COPD
  • 批准号:
    nhmrc : GNT1059239
  • 项目类别:
    Project Grants
  • 资助金额:
    $117.96万
  • 财政年份:
    2014
  • 负责人:
    Prof Matthew Cooper
  • 依托单位:
Modification of the microbiome and utilisation of microbial products as novel treatments for COPD
  • 批准号:
    nhmrc : 1059239
  • 项目类别:
    Project Grants
  • 资助金额:
    $81.77万
  • 财政年份:
    2014
  • 负责人:
    Prof Matthew Cooper
  • 依托单位:
海外基金